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Abstract
Background: Pediatric oncology has a strong research culture. Most pediatric oncologists are investigators,
involved in clinical care as well as research. As a result, a remarkable proportion of children with cancer enrolls in a
trial during treatment. This paper discusses the ethical consequences of the unprecedented integration of research
and care in pediatric oncology from the perspective of parents and physicians.
Methodology: An empirical ethical approach, combining (1) a narrative review of (primarily) qualitative studies
on parents’ and physicians’ experiences of the pediatric oncology research practice, and (2) comparison of
these experiences with existing theoretical ethical concepts about (pediatric) research. The use of empirical
evidence enriches these concepts by taking into account the peculiarities that ethical challenges pose in
practice.
Results: Analysis of the 22 studies reviewed revealed that the integration of research and care has consequences
for the informed consent process, the promotion of the child’s best interests, and the role of the physician (doctor
vs. scientist). True consent to research is difficult to achieve due to the complexity of research protocols, emotional
stress and parents’ dependency on their child’s physician. Parents’ role is to promote their child’s best interests,
also when they are asked to consider enrolling their child in a trial. Parents are almost never in equipoise on trial
participation, which leaves them with the agonizing situation of wanting to do what is best for their child, while
being fearful of making the wrong decision. Furthermore, a therapeutic misconception endangers correct
assessment of participation, making parents inaccurately attribute therapeutic intent to research procedures.
Physicians prefer the perspective of a therapist over a researcher. Consequently they may truly believe that in the
research setting they promote the child’s best interests, which maintains the existence of a therapeutic
misconception between them and parents.
Conclusion: Due to the integration of research and care, their different ethical perspectives become intertwined in
the daily practice of pediatric oncology. Increasing awareness of what this means for the communication between
parents and physicians is essential. Future research should focus on efforts that overcome the problems that the
synchronicity of research and care evokes.
* Correspondence: m.c.de_vries@lumc.nl
1Department of Pediatrics, Leiden University Medical Center, J6-S, PO Box
9600, 2300 RC Leiden, The Netherlands
Full list of author information is available at the end of the article
de Vries et al. BMC Medical Ethics 2011, 12:18
http://www.biomedcentral.com/1472-6939/12/18
© 2011 de Vries et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Background
Children treated for cancer are increasingly likely to sur-
vive. For all childhood cancers combined, 5-year overall
survival has improved over the past 30 years from less
than 20% to about 75%, due to improved treatment and
supportive care [1,2]. A major factor contributing to
these advances is the systematic research effort in pedia-
tric oncology. Pediatric oncology has a strong research
culture. This is instigated by two circumstances: evi-
dence from research with adults with cancer cannot be
generalized to children and childhood cancer is a rarity.
If long delays in making evidence-based treatments
available to children with cancer are to be avoided, it is
important that trials in pediatric oncology recruit a
much greater proportion of the patient population than
adult cancer trials. As a consequence, most pediatric
oncologists are investigators involved in both clinical
care and research.
In the setting of pediatric oncology most treatments
are given according to national or international proto-
cols which describe in detail the treatment plan for each
type of cancer. Protocols represent the best available
treatment at a given moment according to the published
medical literature, but may also include research com-
ponents which contain potential improvements of the
treatment. Table 1 shows different types of research
which are often performed during treatment. As a result
of these research efforts, a remarkable proportion of
children with cancer - up to 70% of children in the
developed world - enrolls in a study during their cancer
treatment, as compared to only 1-4% of adult patients
[3-5]. Due to the integration of research and care the
pediatric oncology practice always faces ethical chal-
lenges inherent to research participation.
The aim of this paper is to describe the ethical conse-
quences of the fading boundary between research and
care from the perspective of parents and physicians. We
present an empirical ethical approach using a narrative
review of existing empirical research evidence on par-
ents’ and physicians’ experiences of the integration of
research and care. The use of empirical evidence
enhances moral thinking by taking into account the
peculiarities and difficulties that ethical challenges pose
in practice. The results therefore remain much closer to
the particular reality of the ethical consequences than a
theoretical paper would permit [6].
Methodology
A narrative review within empirical ethics
In ethics, the use of empirical evidence has become more
and more popular, leading to a distinct form of applied
ethics, namely empirical ethics. Especially in bioethics, this
‘empirical turn’ is visible [7]. Empirical ethics is a broad
category, grasping different interpretations of integrating
ethics and empirical research. There is, however, one basic
assumption in all sorts of empirical ethics: the study of
people’s actual moral beliefs, intuitions, behavior and rea-
soning in a practice yields information that is meaningful
for ethics [8]. It denies the structural incompatibility of
empirical and normative approaches, and believes in their
fundamental complementarity. It is an answer to the cri-
tique of bioethics for being too abstract, too general, too
dogmatic, as well as too far removed from clinical reality,
insensitive to the peculiarities of specific situations.
To gain empirical information, we conducted a narra-
tive review of (primarily) qualitative studies on experi-
ences of parents and physicians in the pediatric
oncology research practice. We subsequently confronted
these experiences with existing theoretical ethical con-
cepts about (pediatric) research, namely goals of
research, informed consent, best interests, equipoise and
therapeutic misconception. In other words, the theoreti-
cal ethical concepts were the starting point and were
subsequently enriched by the emergent themes from the
narrative review. The experiences of parents and physi-
cians give us unique insights in the research practice
and the way ethical concepts function in this practice.
Because we use empirical findings we come much closer
to the reality of the ethical challenges faced than a theo-
retical paper could [6,9].
Two of the authors reported previously on the impor-
tance and the methodology of using empirical findings
Table 1 Description of different types of research in pediatric oncology
Type of research Description
Randomized Controlled Trials
(RCT)
The random allocation of different treatments to patient-subjects. The best available treatment is compared to
one or more regimens that are expected to either improve overall survival or lessen toxicity with equivalence of
outcome. Most ‘front-line’ pediatric cancer studies are phase III randomized controlled trials.
Clinical Controlled Trial (CCT) Evaluation of singe-arm treatment protocols by clinical and epidemiological data collection and systematic
analysis of disease characteristics, actual treatment, treatment results and side-effects. Current treatment results
are compared to historical results and to results obtained by other research groups.
Laboratory research using tissue
from patients
Unraveling the pathogenesis of childhood cancers, characterization of tumor biology, detection of new
treatment targets and identification of novel prognostic factors. For this purpose left over blood, bone marrow
or cerebrospinal fluid is used, or additional biological specimens are taken at defined moments during
treatment. In fact, permission is often asked for storage of biological materials in a cell bank for future, as yet
not specified research.
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to inform moral thinking [6]. The authors used the
same methodology in a paper on discussing infertility
risks and semen cryopreservation with male adolescents
diagnosed with cancer [10] and in a paper on informed
consent in pediatric oncology research [11].
Literature search
An initial work-up established that the literature was too
heterogeneous to permit a systematic review of qualita-
tive studies along the lines proposed by Dixon-Woods
[12]. Furthermore, a systematic review would not permit
a wide and comprehensive scope and the opportunity to
cover a wide range of issues (concepts) within the topic
of pediatric oncology research ethics [13]. For these rea-
sons, a narrative review was undertaken.
Studies included in the review were identified by key-
word searches of Web of Science, Picarta, Pubmed,
Cochrane and EMBASE. Keywords searched included
‘oncology’, ‘clinical trials’, ‘pediatric*’, ‘decision making’,
‘informed consent’, ‘parents’, randomized controlled
trials’ in combination with ‘qualitative study’, ‘semi-
structured’, ‘ethnograph*’ and ‘experiences’. Manual
searches of other relevant journals (JCO, Pediatric Blood
and Cancer, Journal of Pediatric Hematology and Oncol-
ogy, Pediatrics) and reference lists of primary articles
found from initial searches were also conducted.
The focus of the review was on the research types
described in Table 1. Other types of research, especially
phase I and II studies, are also performed in the pedia-
tric oncology setting. However, the described three types
of research have typically become integrated into pedia-
tric oncology practice in such a way that, in contrast
with phase I and II studies, almost all patients and their
parents are confronted with them at the start of initial
treatment. The ethical challenges of phase I and II stu-
dies fall beyond the scope of this paper, because these
studies are usually applied in second line treatment and
are not part of initial treatment protocols.
The median age of children diagnosed with cancer is
below 6. Therefore it is assumed in this paper that the
child is not competent, and that parental authority and
the physician’s care are the main factors in determining
the best interest of the child. We discussed the difficul-
ties of obtaining assent and consent for research from
older children elsewhere [11]. Studies focusing on chil-
dren’s experiences were excluded. In common with
other narrative reviews, evaluations of methodological
quality were not used to exclude papers.
The search revealed 20 qualitative studies, 1 quantita-
tive study, and 1 combination of a quantitative question-
naire and qualitative interviews. Not all studies focus
(only) on the pediatric oncology research context, but
(also) on adult and clinical context. These studies were
still included because they provided important
information on especially physicians’ attitudes towards
research and their conflicting professional roles of physi-
cian and investigator. For this topic, it was not necessary
to have a pediatric setting. Table 2 summarizes the 22
study characteristics, including setting (pediatric vs
adult, research vs clinical context), methodology applied
(interviews, observations, questionnaire) and perspective
(parents, physician).
The existing (theoretical) ethical concepts about
research were studied using ETHX on the web, Philoso-
pher’s Index and Bioethics Line. We focused on
‘research goals’, ‘informed consent’, ‘best interests’, ‘equi-
poise’ and ‘therapeutic misconception’.
Articles and books were included up to January 2011.
Results and Discussion
Analysis of the 22 studies reviewed revealed four main
themes: intertwinement of research and treatment goals,
problems with informed consent, promoting best inter-
ests in a research setting and therapeutic misconceptions.
Goals of research and care: who’s best interest?
One of the consequences of the fading boundary
between research and clinical care is that the goals of
research and treatment become intertwined. From an
ethical point of view, the goals of treatment and
research are fundamentally different [14,15]. In the
treatment relationship, the best interests of the indivi-
dual child prevail when treatment options are discussed.
Generation of new knowledge is incidental compared to
the overriding goal of providing optimal therapy. In the
context of research, the researcher seeks to advance
knowledge about what could be the best care of chil-
dren, as well as to serve other interests like academic
merit. Therapeutic benefits to the individual child are,
in the research perspective, secondary to the overriding
goal of obtaining robust data and new knowledge. Chil-
dren therefore may have to undergo procedures that are
not determined by the goals of treatment, like additional
blood samples, spinal taps and (PET-) scans.
The different ethical perspectives of treatment and
research can also be illustrated by the different types of
ethical principles governing the two activities [14,16,17].
In the context of pediatric treatment the principles of ben-
eficence and non-maleficence dictate the practice, trans-
lated in the statement that treatment should be in the best
interest of the individual child. Usually parents and physi-
cians share the same ideas on what constitutes the child’s
best interest, making it possible to use the concept of
implicit consent. In the context of research, however, ben-
eficence also involves benefits to others. The prevailing
principle therefore is respect for autonomy. Respect for
autonomy incorporates two ethical convictions: firstly, that
individuals should be treated as autonomous subjects, and
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secondly, that persons with diminished autonomy are
entitled to protection [14] Respect for autonomy demands
that subjects voluntarily participate in research, with ade-
quate information and only after explicit consent. In the
case of incompetent subjects, like young children, there
should be vigorous protection against abuse, and substi-
tute permission should be sought. Due to the integration
of research and care, their different ethical perspectives
must simultaneously be applied in the daily practice of
pediatric oncology. This has consequences for the
informed consent process, the promotion of the best inter-
est of the child by parents, and the role of the physician
(doctor vs. scientist).
Informed consent in the pediatric oncology research setting
Joffe and all have shown that the context of pediatric
oncology contains many obstacles to a good informed
consent process [18], especially when discussions
Table 2 Summary of study characteristics
Author & Date [reference] Setting Methodology Sample characteristics
Vries e.a. 2010 [11] Pediatric oncology
clinical research
- Retrospective interviews Physicians
n = 15
Kodish e.a. 2004 [23] Pediatric oncology
clinical research
- Observations
- Retrospective interviews
Parents
n = 137
Wiley e.a. 1999 [24] Pediatric oncology
clinical research
- Questionnaire (retrospective) Parents
n = 192
Stevens e.a. 2002 [25] Pediatric oncology
clinical research
- Retrospective interviews Parents
n = 12
Chappuy e.a. 2010 [27] Pediatric oncology
clinical research
- Retrospective interviews Parents
n = 43
Dermatis e.a. 1990 [28] Pediatric oncology
clinical research
- Questionnaire (retrospective) Parents
n = 61
Levi e.a. 2000 [29] Pediatric oncology
clinical research
- Focus group interviews (retrospective) Parents
n = 22
Van Stuijvenberg e.a. 1998 [31] Pediatric general practice
clinical research
- Questionnaire (retrospective) Parents
n = 181
Tait e.a. 1998 [32] Pediatric anesthesia
clinical research
- Questionnaire (retrospective) Parents
n = 246
Singhal e.a. 2002 [34] Neonatology
clinical research
- Questionnaire (retrospective) Parents
n = 231
Reynolds e.a. 2007 [35] Pediatric endocrinology
clinical research
- Interviews (hypothetical decisions about research) Parents
n = 31
Kupst e.a. 2003 [36] Pediatric oncology
clinical research
- Retrospective interviews Parents
n = 20
Snowdon e.a. 1997 [37] Neonatology
clinical research
- Questionnaire (retrospective)
- Retrospective interviews
Parents
n = 71
Eiser e.a. 2005 [38] Pediatric oncology
clinical research
- Retrospective interviews Parents
n = 50
Heneghan e.a. 2004 [40] Pediatric general practice
No research
- Focus group interviews Parents
n = 44
McKenna e.a. 2010 [45] Pediatric oncology
clinical research
- Questionnaire (retrospective)
- Retrospective interviews
Parents
n = 66
Appelbaum e.a. 1982 [46] Adult psychiatry
clinical research
- Observations
- Retrospective interviews
Adult patients
n = 31
Joffe e.a. 2001 [48] Adult oncology
clinical research
- Questionnaire (retrospective) Adult patients
n = 207
Taylor 1992 [50] Adult oncology
clinical research
- Questionnaire (retrospective)
- Retrospective interviews
Physicians
n = 101
Taylor e.a. 1994 [51] Adult & pediatric oncology
clinical research
- Questionnaire (retrospective - quantitative study)
- Retrospective interviews (n = 43)
Physicians
n = 1485
Joffe e.a. 2002 [52] Adult & pediatric oncology
clinical research
- Questionnaire (retrospective)
(quantitative study)
Physicians
n = 547
Instone e.a. 2008 [61] Adult gastroenterology
clinical research
- Observations
- Retrospective interviews
Physicians + nurses, n = 19
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regarding diagnosis and treatment include dialogue
about participation in research. Parents have the difficult
task to differentiate between research and clinical issues,
for example when talking about goals and risks.
Informed participation in decision making requires ade-
quate understanding of treatment options, but simulta-
neously the understanding of the distinction between
research and therapeutic intent and of difficult research-
related concepts, such as randomization, voluntariness
and the risk-benefit ratio. The consent forms involved,
explaining concepts and methods, are complex by nat-
ure and difficult to understand [19-22]. Studies show
that parents frequently have an incomplete understand-
ing of the necessary elements of informed consent in
research, especially of the risks, the procedures, the pos-
sibility of alternative treatments, the duration of partici-
pation, their right to withdraw, and the voluntariness of
participation [23-25]. A reason for this incomplete
understanding might be that the standard treatment
protocols often include research interventions, like extra
blood draws, or a randomization, as if these research
elements were an integral part of the treatment. For
example, the Dutch protocol for acute lymphoblastic
leukemia (ALL) states in the parent information form:
“Almost all children with ALL are treated according to
a national protocol of the Dutch Childhood Oncology
Group or according to an international protocol. A pro-
tocol contains guidelines for research and the mode of
treatment” [26].
This can make parents think that when they consent
to the protocol, they consent to the treatment as well as
to the research elements, and that it is not an option
only to accept the treatment and to decline research
participation [27].
The literature also shows that physicians find it difficult
to obtain truly informed consent for complex treatment
and research proposals from parents who are emotionally
distressed because their child has a life threatening condi-
tion [18,28]. The extraordinary psychological strain influ-
ences physician-parent communication and limits its
potential effectiveness, especially when decisions about
research participation need to be made within hours or
days [29]. The emotional setting of (pediatric) oncology
puts in this way great trust on the acting physician who
raises treatment and research options [30,31]. In fact, con-
sent for research is often based on the relationship of trust
which exists in the care setting between the physician and
the parents [28,32].
Consequently, in the pediatric oncology setting true
consent from parents for research is difficult to obtain.
Promoting best interests from a parental point of view
The primary responsibility of parents is to care for and
protect their child, also when parents are asked to
consider enrolling their child in a pediatric clinical trial
[33]. This responsibility makes it difficult for them to
think of a research setting as detached from the best
interests of their child. Of course parents often state
that they are motivated to support research that may
improve the chances of future patients. They acknowl-
edge that the participation of other children in former
trials has improved treatment to the benefit of their
own child and they are prepared to do likewise. But pro-
tecting their child is fundamental to the parental role
and this shapes how they think about trials [32]. Some
form of altruism can play a role in deciding to let a
child participate in research, but only with the firm con-
viction that the research will not pose any harm to the
child, and even more, with the prospect that the
research will benefit the child [34,35].
Parents will take many different factors into account
when deciding whether or not to let their child enter an
RCT and will not simply accept randomization because
an ethics committee has deemed it permissible. For
some parents, randomized trials may represent the pro-
spect of receiving a new treatment with a potentially
important direct benefit to their child [36]. If this new
treatment is only available within a trial, parents may
consent to their child’s entry for the chance of receiving
the assumed benefits [37]. It can cause them to antici-
pate regret for not at least trying to get this new treat-
ment through research participation, all from their
perspective as guardian of the interests of their child.
The question whether a potential benefit will become
available through participation in research is particularly
germane. It can be hard for parents to understand that
a study involves a new, and in their view potential better
therapy for their child, but that research methodology
involves randomization, and that the child can also draw
the standard therapy [38]. On finding that their child
has been allocated to the standard arm, parents some-
times report a sense of missed opportunity, as if the
child has been deprived of a known beneficial treatment
[32]. This may lead to unwanted tensions between par-
ents and physicians at the outset of a long treatment
relationship.
On the other hand, parents can also hesitate to parti-
cipate because of fears for an ‘experimental’ arm, of
being used as a ‘guinea pig’, or of a computer choosing
what therapy will be given [36].
The treating physician and the investigator are often
the same person. This can make parents fear that refusal
will have consequences for their future relationship with
the physician. Parents frequently indicate that they find
it difficult to oppose the proposal of the physician,
because they are afraid that this might jeopardize the
relationship with the physician, even though consent
forms explicitly state the opposite [39,40].
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Whatever arm of a trial parents think is better for
their child, their preference shows that the idea of clini-
cal equipoise held by the expert medical community is
not directly transferable to the parent setting. For par-
ents the different arms of a trial are often not in equi-
poise. Firstly, because they can hold the conviction that
one arm is medically superior [36-38]. Secondly because
the arms may differ in duration or in the amount of
extra visits or blood draws. The personal context of a
family then determines whether or not a trial arm fits to
this family. For example, parents may prefer one trial
arm because they live long distance from the hospital
and the preferred arm contains less extra visits. Parental
equipoise would be the point at which the parents are
‘maximally uncertain’ regarding the relative efficacy,
safety and fittingness to their personal situation of com-
parator interventions. Parental equipoise has not been
described before, but could be seen as the ‘proxy ver-
sion’ of patient equipoise. When Freedman defined
(clinical) equipoise, he stated that it is the expert medi-
cal community that ought to be in equipoise [41]. In the
literature however, it is argued that not only the medical
expert community should be in equipoise, but also the
trial participants themselves [42,43]. London argues that
this has consequences for the informed consent process:
“There may be reasons that might lead a potential
trial participant to prefer one treatment over another
even though expert opinion is conflicted. (...) When this is
the case, participating in a clinical trial may not be a
permissible option for that patient. (...) This example (...)
provides a clear focus for the goals of the informed con-
sent process: to ensure that only those individuals parti-
cipate in research who see the clinical trial as a
reasonable option in light of the conflict or uncertainty
that exists in expert medical opinion.” [[42], p.584].
This resembles Hans Jonas’ argument that the people
who should be enrolled in a clinical trial should be the
ones who most identify with the cause of research [44].
The mentioned literature [32-38] shows that parental
equipoise is often very difficult to reach, which leaves
parents with the agonizing situation of wanting to do
what is best for their child, while not knowing whether
research participation is the best course of action to
achieve this and being fearful of making the wrong deci-
sion [45].
Therapeutic Misconception
Parents can mix up research and treatment goals
[23-25,27]. Failure to appreciate the difference between
the context of research and treatment, and therefore
inaccurately attributing therapeutic intent to research
procedures is called ‘the therapeutic misconception’
[46,47]. It refers to the research subject’s failure to
appreciate that the aim of research is to obtain scientific
knowledge, and that any benefit to the subject is a side
product of that goal. Though the data are scarce, there
is evidence that many trial participants in oncology hold
therapeutic misconceptions [23,48]. One study found
that 40-80% of subjects show basic misunderstandings
of the research trial design [49].
Due to the fading boundary between research and care
in pediatric oncology therapeutic misconceptions can
easily arise. This puts another burden on the process of
informed consent during which parents will have to be
made aware that the proposed treatment is not selected
only because of the individual needs of the patient.
The physician’s perspective: doctor vs. scientist
Not only parents find it difficult to distinguish treatment
and research goals. Physicians and other health person-
nel may also experience problems when research and
clinical care are performed simultaneously. The tradi-
tional division of tasks in clinical or research-related is
challenged by the emergence of randomized controlled
trials (RCTs) and clinical controlled trials (CCTs, see
also Table 1) [50]. Physicians may experience tension
between their roles as clinicians and scientists, since the
latter defies the traditional definition of their core task
to place the best interests of patients first. As a solution
most oncologists, even those with substantial trial invol-
vement, focus first of all on the possible benefit to their
immediate patient and not on the theoretical benefit of
future patients. In this way they adopt the perspective of
a therapist rather than that of a researcher [51]. Studies
show that many oncologists really feel that research par-
ticipation is in the best interest of the individual child
[11,52]. This can be understood in two ways. Firstly,
physicians feel confident that trials are not harmful, and
that control by an Institutional Review Board (IRB) pro-
tects the child. Secondly, physicians believe that being in
a trial, independently of the arm the patient is in, is
even better than receiving the same treatment outside of
the trial [11]. Enrolling children in clinical trials would
ensure that they receive the best treatment. The website
of the M.D. Anderson Cancer Center, one of the leading
centers for cancer research and care, states underneath
a list of diseases for which clinical trials are available:
“When you are offered to participate in a clinical trial,
your doctor has decided that the best treatment for your
condition is provided in that trial” [53].
This suggests that trials are viewed not only as a way
to improve treatment in the future, but also as the
best treatment for current patients. Pediatric oncolo-
gists tend to view trial protocols as clinical practice
guidelines [52]. The statements by many leaders in
oncology that clinical trials represent the optimum
care for cancer patients are also an expression of this
view [54,55].
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It could be argued that a RCT does preserve the basic
duty to act in the best interest of the child because of
clinical equipoise. After all, no subject is randomized to
a treatment known to be inferior to the standard treat-
ment. But the fundamental difference between research
and treatment is that the treatment setting requires an
experienced clinician who selects and monitors the
treatment taking into account individual, person-specific
factors. The setting of a RCT requires that once a child
is thought eligible for participation, the investigator
renounces patient specific considerations and uses ran-
domization and a meticulously followed protocol in
order to get generalizable results. (Of course taking into
account that a child will be removed from a study if it is
not in the its interests to remain in the study and also
that treatments will be adjusted if a child is too unwell
to tolerate them.) Especially when experimental treat-
ments are evaluated, the risks and benefits in rando-
mized trials are less fixed than those in standard
medical care. It is the hallmark of randomized studies
that it is never known in advance what the actual risks
and benefits will be: only after the completion of a study
one genuinely knows which arm of the trial showed the
best results and whether or not participants were
exposed to extra risks and burdens in the intervention
arm. Kumar et al. [56] described 126 RCTs within the
setting of the Children’s Oncology Group. They showed
that new (experimental) treatments are as likely to be
inferior as they are to be superior to standard treat-
ments. Most pediatric oncology trials have Data and
Safety Monitoring Plans (DSMP) and suspension rules
for the very purpose of dealing with unexpected risks
and outcomes.
It has been argued that trial participation is beneficial
as compared to non-participation because of the strict
adherence to well-defined protocols. Various authors
have shown that the use of a treatment protocol
improves the end result of that treatment [57,58]. This
would be due to the explicit description of treatment
phases and follow up and to strict guidelines indicating
how to deal with side effects and relapses. For CCTs
one could conclude that participation is beneficial, since
CCTs are single arm studies in which the best available
treatment is laid down in a protocol (to be able to com-
pare treatment results to historical results). But it is
more difficult to apply this to RCTs. A Cochrane review
assessed whether there were beneficial effects from par-
ticipating in RCTs [59]. The outcomes of patients who
participated in RCTs were compared with outcomes of
patients who received similar clinical interventions out-
side the RCT. On average, the outcomes were similar,
suggesting that participation in RCTs does not result in
improved outcomes. Peppercorn et al. therefore state:
“Despite widespread belief that enrollment in clinical
trials leads to improved outcomes in patients with can-
cer, there are insufficient data to conclude that such a
trial effect exists. Until such data are available, patients
with cancer should be encouraged to enroll in clinical
trials on the basis of trials’ unquestioned role in improv-
ing treatment for future patients” [60].
The belief that enrolling children in RCTs ensures
that they receive state-of-the-art treatment and that par-
ticipation is best for the individual child is therefore an
example that the therapeutic misperception may also be
fostered by physicians [61].
In conclusion, the physician-investigator has a
‘hybrid’ identity. He serves two different goals: the
best interest of the patient and scientific progress
(and thereby the best interest of future patients). Phy-
sicians are more likely to prefer the perspective of a
therapist over that of a researcher, and consequently
they may truly come to believe that in the research
setting they promote the child’s best interests. With
this position physicians potentially promote the exis-
tence of a therapeutic misconception between them
and parents.
Some authors contend that, to reduce misunderstand-
ings about the nature and purpose of research, physi-
cian-investigators should restrict themselves to being
scientists only and not doctors [62]. In this way the ethi-
cal insistence on a clear boundary between research and
clinical activity can be secured. This could also partially
be achieved by letting research nurses carry out
informed consent conversations with parents and chil-
dren. In both situations, the role of the researcher and
the goal of research may be clearer. This solution would
however require a fundamental change in the pediatric
oncology practice and as such might raise its own pro-
blems, for instance regarding the available health per-
sonnel and communication problems between
physicians and researchers.
Limitations
The studies included in the narrative review have limita-
tions that should be acknowledged. Most studies are
interview or questionnaire studies using a retrospective
design. In this design there can be uncertainty whether
the parents’ and physicians’ recollections were accurate
representations of how they felt and what their thoughts
were at the time of diagnosis and inclusion in a trial.
Only 3 studies used a prospective design (see Table 2).
Most studies have small sample sizes. Future research
with larger samples and a prospective design will be
able to ascertain the relationship between the specifics
of the informed consent discussion and parental and
physician recollection.
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Conclusion
There is an urgent need for high-quality research in
children, to ensure that drugs used in the pediatric set-
ting are both safe and effective [63]. Pediatricians must
often rely on evidence that has been generated in adult
populations [64], although both the safety and efficacy
profiles of drugs may be significantly different for chil-
dren [65]. Therefore it is of vital importance to enroll
children with cancer in clinical studies. The pediatric
oncology practice shows that general implementation of
clinical research continuously improves outcomes for
children with cancer. However, when research and
clinical care coincide as much as in the pediatric oncol-
ogy setting, several ethical problems can come up.
Firstly, parental equipoise is almost never reached.
Parents cannot (and are not supposed to) think beyond
the scope of the best interests of their child. To consider
the goals of research per se is very difficult, if not
impossible for them. Due to the diminishing boundary
between research and care, parents are confronted with
alleged options and treatment choices, which eventually
turn out to be only accessible through research. Some
parents are confronted with anticipated remorse when
not participating in (promising) research. Others fear
Table 3 Awareness points and recommendations for communication in relation to type of research
Type of research Awareness* Recommendations for communication
Randomized Controlled
Trials (RCT)
Confidentiality and privacy
The potential for a therapeutic
misconception:
- differences between clinical research and
standard care
- potential conflict between research
and treatment goals
Consent to treatment does not imply
consent to an RCT
Provide information about collection of data and measures
taken to protect confidentiality and privacy.
Clarify how the physician-investigator/patient-subject
relationship differs from the traditional physician-patient
relationship.
Mention alternatives to research participation explicitly.
Discuss clinical and parental equipoise.
Mention voluntariness.
Indicate research interventions that are solely performed to
measure trial outcomes.
Assure freedom to withdraw from the study.
Discuss research participation with subjects before, during
and after the study.
Ask explicit consent with a separate consent form than the
consent form for treatment. Ask consent for treatment first,
and for research later, preferably by a different person than
the treating physician, for example a research nurse (with the
opportunity to consult with the treating physician)
Clinical Controlled Trial
(CCT)
Confidentiality and privacy
Consent to treatment does not imply
consent to collect patient data
Provide information about collection of data and measures
taken to protect confidentiality and privacy.
Ask explicit consent with a separate consent form than the
consent form for treatment. Ask consent for treatment first,
and for research later, preferably by a different person than
the treating physician, for example a research nurse (with the
opportunity to consult with the treating physician)
Laboratory research using
tissue from patients
Confidentiality and privacy
No therapeutic goal; completely distinct
from therapeutic interventions
The obligation of non-maleficence in this
setting differs from that in clinical
medicine
Consent to treatment does not imply
consent to using or storing human
tissues for research purposes
Provide information about collection of data and measures
taken to protect confidentiality and privacy.
Mention voluntariness.
Indicate that all research interventions to gain tissues are
solely performed to gain scientific knowledge.
Indicate that risks to a patient are justified not because they
are outweighed by potential benefits to the patient, but
because they are outweighed by the value of the knowledge
to be gained from the research.
Ask explicit consent with a separate consent form than the
consent form for treatment. Ask consent for treatment first,
and for research later, preferably by a different person than
the treating physician, for example a research nurse (with the
opportunity to consult with the treating physician)
* Confidentiality and privacy are not explicitly discussed in this paper. Apparently, parents and physicians do not experience these concepts as problematic or
are not aware of them. Still, confidentiality and privacy are basic concepts in research ethics and should be discussed with parents. For completeness they are
mentioned in the Table, in order for the Table to be used as a list to ‘tick off’ when communicating research with parents.
de Vries et al. BMC Medical Ethics 2011, 12:18
http://www.biomedcentral.com/1472-6939/12/18
Page 8 of 11
trials because of the experimental nature. Many experi-
ence a lack of freedom to reject participation. Secondly,
the therapeutic misconception may endanger a correct
assessment of the pros and cons of participation,
because parents might inaccurately attribute therapeutic
intent to research procedures. Their focus on the thera-
peutic effect may hamper understanding of the research
purposes. All this could lead to a feeling of emotional
stress and limited voluntariness that is reinforced by the
trust that is often inherent to the relationship between
physician and parents, especially in pediatric oncology
[66].
Physicians too are constrained in their options because
of their conviction that research constitutes the best
available treatment, thereby passing over the greater
uncertainty of the risk-benefit ratio as compared to
standard medical care.
The challenges that a lack of parental equipoise and
the therapeutic misconception pose may be very difficult
to overcome. Thorough attention to the quality of com-
munication of research information could improve
understanding of the research perspective [16,67]. In
Table 3 we summarize points of awareness with respect
to research discussions and give recommendations to
improve communication. But even in the case of an
enormous communication effort, the question remains
whether it is truly possible to explain the nature of
research and thereby overcome the emotional conflict of
parents who feel responsible for their child’s wellbeing.
Future research should focus on special efforts that
might achieve this.
As it stands today, physicians are bound to react to
the individual needs and expectations of parents and
children within the context of research. The physician-
investigator needs to be convinced that the best interests
of the child are warranted. This means that both a ther-
apeutic and a scientific orientation are appropriate, and
the physician needs to shuttle between clinical care
duties and research duties. To do this ethically, he con-
tinuously needs to be aware of the potential conflict
between research and treatment goals (see Table 3).
Having considered all this, professional integrity requires
the physician to treat both the patient’s interests and the
scientific interests in an honest way without backsliding
into a form of therapeutic misconception. After all, he
has committed himself to serve both.
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